Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 3/20 | 0.39 |
| ▸ | NOS2 | P35228 | 3/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 9/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4557504 | 1.00 | ALOX5 (0.50) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL1437889 | 1.00 | ALOX5 (0.50) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL176362 | 0.97 | — | — | |
| SCHEMBL31274418 | 0.89 | — | — | |
| SCHEMBL5147443 | 0.89 | — | — | |
| SCHEMBL24951394 | 0.89 | ALOX5 (0.47) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| Bicarbonate SCHEMBL11801812 | 0.89 | ALOX5 (0.61) | ALOX5ALDH1A1TSHR | |
| SCHEMBL19302096 | 0.87 | ALOX5 (0.42) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| SCHEMBL19302125 | 0.87 | ALOX5 (0.42) | ALOX5ALDH1A1EPHX1TSHRTHRB | |
| Ammonia Solution, Strong SCHEMBL20492536 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065079-A1 | FATTY ACID DERIVATIVE LABELED WITH POSITRON-EMITTING RADIONUCLIDE | ASTELLAS PHARMA INC. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2013116126-A1 | NOVEL LOW MOLECULAR WEIGHT, BIODEGRADABLE CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-1846111-B1 | DECONTAMINANT | BATTELLE MEMORIAL INSTITUTE (US) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065079-A1 | FATTY ACID DERIVATIVE LABELED WITH POSITRON-EMITTING RADIONUCLIDE | FABP3, SLC27A1, FASN | ALOX5 187/4885ALDH1A1 276/4885EPHX1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.